A new report, "Dementia - Global Clinical Trials Review, 2024," provides a comprehensive analysis of the dementia clinical trial landscape, offering insights into trial numbers, enrollment trends, and key players across the globe. The report, collated from over 80 clinical trial registries, conferences, journals, and news sources, aims to enhance decision-making capabilities and inform effective counter-strategies for gaining a competitive advantage in the field.
Global Trial Overview
The report offers a snapshot of the global clinical trials landscape, providing top-level data related to clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status. It reviews top companies involved and lists all trials (trial title, phase, and status) pertaining to each company. The analysis also includes unaccomplished trials (terminated, suspended, and withdrawn) with the reason for their incompletion.
Regional and Country-Specific Data
The analysis delves into regional specifics, highlighting the top five countries contributing to clinical trials in various regions, including Asia-Pacific, Europe, North America, the Middle East and Africa, and Central and South America. It also provides a comparison of dementia clinical trials to central nervous system clinical trials within the G7 and E7 countries, broken down by phase and trial status.
Enrollment Trends and Sponsor Analysis
The report examines enrollment trends over the past five years and analyzes clinical trials by sponsor type, identifying prominent sponsors in the dementia research space. It also highlights the top companies participating in dementia therapeutics clinical trials and lists prominent drugs currently under investigation.
Key Companies and Drugs
The report identifies several key companies involved in dementia therapeutics clinical trials, including Eisai Co Ltd, Johnson & Johnson, Eli Lilly and Co, Novartis AG, C. H. Boehringer Sohn AG & Co KG, Forest Laboratories LLC, Teva Pharmaceutical Industries Ltd, The Lundbeck Foundation, Otsuka Holdings Co Ltd, and AstraZeneca Plc. The report also identifies prominent drugs being investigated in these trials.
Strategic Implications
The report assists in formulating key business strategies regarding investment, helps in identifying prominent locations for conducting clinical trials, provides top-level analysis of the Global Clinical Trials Market, supports understanding of trials count and enrollment trends by country, aids in interpreting the success rates of clinical trials, and facilitates clinical trial assessment of the indication on a global, regional, and country level.
